

## Descriptions of the Three Current Therapies Offered by LSOW, Inc.

By: Victer Muhammad, B.S., M.S., Ph.D.(incomp)
Executive Director - Life Sciences of Washington, Incorporated

## 22 September 2020

Note: This document is the property of Victer Muhammad. No portion of this document may be reproduced in any form without the expressed written permission of the author except, in the case where the document is published, in its entirety, without any changes.

This Document contains the three therapies currently offered by Life Sciences of Washington, Incorporated (LSOW).

- I. ImmunBoost 100 (IB 100): This is a product that contains the requisite proteins amino acids necessary the actions of most viral infections. The IB 100 has a 27-year history and has been successful in the reversal of a multitude of maladies affecting the human animal.
- II. ImmunBoost 30 (IB 30): This product is a derivative of the IB 100. Some instances of human health do not require arresting an infection but suggests "Prevention". This is the need out of which the IB 30 was borne.
  - LSOW, Inc. recommends, in one such scenario, the human begins a regimen of IB 30 in mid-July. As such, by the time of the onslaught of cold/flu season, the recipient will have an immune response capable of combating and resisting the toxicity level in viral growth that is termed a "cold" or the "flu".
- III. ImmunBoost 19 (IB 19): This product contains similar properties as the IB 100. Its Amino Acid sequences are arranged in such manner that said properties successfully combats bacterial infections.



